CYPHERPUNK TECHNOLOGIES INC. CYPH
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
12.06
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | $4.8M | — | — | $153.5M |
| 2024 | — | -$67.6M | — | — | $35.0M |
| 2023 | — | -$81.4M | — | — | $60.1M |
| 2022 | — | -$54.6M | — | — | $58.9M |
| 2021 | $1.5M | -$40.6M | — | — | $107.9M |
| 2020 | $1.5M | -$27.5M | — | — | $46.7M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 12.06 (safe)
- Working capital / assets 0.965
- Retained earnings / assets -2.835
- EBIT / assets -0.252
- Equity / liabilities 15.865
Source: SEC EDGAR filings · CIK 0001509745 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.